News & Updates

Show Multimedia Only

Apixaban vs rivaroxaban for acute VTE: Insights from 1st head-to-head randomised trial

07 May 2026

Direct oral anticoagulants (DOACs) are established as first-line therapy for acute venous thromboembolism (VTE), offering effective thromboprophylaxis with improved safety compared with vitamin K antagonists. [Blood Adv 2020;4693-4738] However, despite the widespread use of apixaban and rivaroxaban in clinical practice, a lack of direct randomised comparative evidence has historically limited clinicians’ ability to differentiate between these agents. The COBRRA trial fills this gap, representing the first head-to-head randomised controlled trial (RCT) comparing apixaban and rivaroxaban in patients with acute VTE. [N Engl J Med 2026;394:1051-1060]

Apixaban vs rivaroxaban for acute VTE: Insights from 1st head-to-head randomised trial

07 May 2026

ACEi/ARBs may prevent death, kidney events in older adults after dialysis, but with caveat

05 May 2026

The use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB) appears to reduce the risk of all-cause mortality and major adverse kidney events (MAKE) in very old adults who underwent dialysis for acute kidney injury (AKI), suggests a study.

ACEi/ARBs may prevent death, kidney events in older adults after dialysis, but with caveat

05 May 2026

Device-based LAAC noninferior to NOAC therapy in AF patients

04 May 2026

In the prevention of stroke in patients with atrial fibrillation (AF), device-based left atrial appendage closure (LAAC) compares favourably with non–vitamin K antagonist oral anticoagulant (NOAC) therapy, with the added advantage of reduced non–procedure-related bleeding, according to the CHAMPION-AF trial.

Device-based LAAC noninferior to NOAC therapy in AF patients

04 May 2026

High-intensity interval training improves exercise capacity in young patients with rToF

03 May 2026

In adolescents and young adults with repaired tetralogy of Fallot (rToF), home-based high-intensity interval training (HIIT) helps increase peak oxygen consumption and maximal workload without increasing the risk of adverse events, as shown in a study.

High-intensity interval training improves exercise capacity in young patients with rToF

03 May 2026

Clopidogrel a feasible alternative to aspirin in post-PCI maintenance phase

03 May 2026

The use of clopidogrel for long-term antiplatelet monotherapy during the maintenance phase after percutaneous coronary intervention (PCI) results in reduced adverse cardiovascular and bleeding outcomes compared with aspirin, as shown in the secondary analysis of the HOST-EXAM study.

Clopidogrel a feasible alternative to aspirin in post-PCI maintenance phase

03 May 2026

Invasive strategy for frail older patients with NSTEMI may do more harm than good

01 May 2026

In the treatment of frail older patients with non–ST-elevation myocardial infarction (NSTEMI), an invasive strategy does not appear to provide additional benefit compared with a conservative strategy and may even contribute to an increased risk of harm in those at the highest levels of frailty, according to the secondary analysis of the SENIOR-RITA trial.

Invasive strategy for frail older patients with NSTEMI may do more harm than good

01 May 2026

Cognitive decline may be a red flag for future cardiovascular risk

30 Apr 2026

Cognitive function deterioration commonly occurs years prior to cardiovascular disease (CVD) events in older adults, as shown in a nested case-control study.

Cognitive decline may be a red flag for future cardiovascular risk

30 Apr 2026

Triple therapy controls hypertension, dyslipidaemia

30 Apr 2026 by

Triple therapy with angiotensin receptor blockers (ARBs)/amlodipine + rosuvastatin significantly reduces blood pressure (BP) and cholesterol levels in patients with hypertension and dyslipidaemia compared with dual therapies involving ARBs/amlodipine or ARBs + rosuvastatin, according to a recent study.

Triple therapy controls hypertension, dyslipidaemia

30 Apr 2026

Residential greenness may protect against post-COVID ischaemic heart disease

29 Apr 2026

Exposure to residential greenness in COVID-19 survivors appears to reduce the risk of chronic ischaemic heart disease but not that of acute coronary events, as reported in a cohort study from South Korea.

Residential greenness may protect against post-COVID ischaemic heart disease

29 Apr 2026

COVID-19 may put hypertensive patients at increased risk of worse CV outcomes

28 Apr 2026 by

New research indicates that among patients with hypertension, COVID-19 contributes to an increased risk of poorer cardiovascular (CV) outcomes.

COVID-19 may put hypertensive patients at increased risk of worse CV outcomes

28 Apr 2026

News & Updates

Showing Cardiology articles

Showing

Specialty:

Apixaban vs rivaroxaban for acute VTE: Insights from 1st head-to-head randomised trial

Apixaban vs rivaroxaban for acute VTE: Insights from 1st head-to-head randomised trial

ACEi/ARBs may prevent death, kidney events in older adults after dialysis, but with caveat

ACEi/ARBs may prevent death, kidney events in older adults after dialysis, but with caveat

Device-based LAAC noninferior to NOAC therapy in AF patients

Device-based LAAC noninferior to NOAC therapy in AF patients

High-intensity interval training improves exercise capacity in young patients with rToF

High-intensity interval training improves exercise capacity in young patients with rToF

Clopidogrel a feasible alternative to aspirin in post-PCI maintenance phase

Clopidogrel a feasible alternative to aspirin in post-PCI maintenance phase

Invasive strategy for frail older patients with NSTEMI may do more harm than good

Invasive strategy for frail older patients with NSTEMI may do more harm than good

Cognitive decline may be a red flag for future cardiovascular risk

Cognitive decline may be a red flag for future cardiovascular risk

Triple therapy controls hypertension, dyslipidaemia

Triple therapy controls hypertension, dyslipidaemia

Residential greenness may protect against post-COVID ischaemic heart disease

Residential greenness may protect against post-COVID ischaemic heart disease

COVID-19 may put hypertensive patients at increased risk of worse CV outcomes

COVID-19 may put hypertensive patients at increased risk of worse CV outcomes